<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02127541</url>
  </required_header>
  <id_info>
    <org_study_id>EKBB 163/12</org_study_id>
    <nct_id>NCT02127541</nct_id>
  </id_info>
  <brief_title>New Imaging Procedure for the Localisation of Insulinoma</brief_title>
  <official_title>New Imaging Procedure for the Localisation of Insulinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Desirée and Niels Yde's Foundation, Zürich, Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Insulinoma: Insulinoma are rare, small insulin secreting neuroendocrine tumors. The only
      curative approach is the surgical excision. The preoperative detection remains a challenge. A
      non-invasive, highly sensitive tool in localizing the insulinomas would be appreciated in the
      preoperative work-up of these patients. To this aim Glucagon-like peptide-1 receptor (GLP-1R)
      imaging (Single Photon Emission Computer Tomography co-registered with a CT; SPECT/CT) could
      be a convenient tool. The possibly more sensitive approach of targeting GLP-1R using Positron
      emission tomography (PET/CT) methodology has not been investigated in patients so far.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 6, 2014</start_date>
  <completion_date type="Actual">November 2017</completion_date>
  <primary_completion_date type="Actual">November 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measuring Tumour to Background Ratio</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measuring the accuracy of the Tumour-Localisation of 68-DOTA-Exendin-4 PET/CT and 111 In-DOTA-exendin-4 SPECT/CT.</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Accuracy of tumour localisation of standardized MRI in comparison with 68-DOTA-Exendin-4 PET/CT and 111 In-DOTA-exendin-4 SPECT/CT</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity of tumour localisation with 68-DOTA-Exendin-4 PET/CT, 111 In-DOTA-exendin-4 SPECT/CT and standardized MRI in comparison with conventional imaging (CT,MRI and EUS)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the side effects of 68Ga-DOTA-exendin-4 and 111In-DOTA-exendin-4</measure>
    <time_frame>4 years</time_frame>
    <description>Through measurement of blood glucose and Quantification of Nausea respectively vomiting by means of the common toxicity criteria score system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the interobserver variability of 68Ga-DOTA-Exendin-4 PET/CT and 111In-DOTA-exendin-4 SPECT/CT</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the angiogenesis markers with the those of breast carcinoma patients</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Endogenous Hyperinsulinaemic Hypoglycaemia</condition>
  <arm_group>
    <arm_group_label>Ga -exendin PET/CT, In- exendin SPECT/CT, MRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a cross-over study comparing three imaging methods (68Ga-DOTA-exendin-4 PET/CT, 111In-DOTA-exendin-4 SPECT/CT, MRI) in the same patient.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ga -exendin PET/CT, In- exendin SPECT/CT, MRI</intervention_name>
    <description>Comparison of different imaging modalities</description>
    <arm_group_label>Ga -exendin PET/CT, In- exendin SPECT/CT, MRI</arm_group_label>
    <other_name>68Ga-DOTA-exendin-4</other_name>
    <other_name>111In-DOTA-exendin-4</other_name>
    <other_name>MRI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biochemically proven endogenous hyperinsulinaemic hypoglycaemia in the fasting state
             with neuroglycopenic symptoms or autologous Islet Cell transplantation in the forearm

          -  Conventional imaging (CT,MRI or EUS) not older than 2 months

          -  Signed written consent

          -  Age above 18 years

        Exclusion Criteria:

          -  Kidney failure (creatinine &gt; 140micromol/l)

          -  Known allergies against Exendin-4 (Byetta or Bydureon)

          -  Pregnancy

          -  Breastfeeding

          -  Medication with Byetta or Bydureon

          -  Evidence for malignancy (extrapancreatic tumor manifestations)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Damian Wild, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Wild D, Mäcke H, Christ E, Gloor B, Reubi JC. Glucagon-like peptide 1-receptor scans to localize occult insulinomas. N Engl J Med. 2008 Aug 14;359(7):766-8. doi: 10.1056/NEJMc0802045.</citation>
    <PMID>18703486</PMID>
  </reference>
  <reference>
    <citation>Christ E, Wild D, Forrer F, Brändle M, Sahli R, Clerici T, Gloor B, Martius F, Maecke H, Reubi JC. Glucagon-like peptide-1 receptor imaging for localization of insulinomas. J Clin Endocrinol Metab. 2009 Nov;94(11):4398-405. doi: 10.1210/jc.2009-1082. Epub 2009 Oct 9.</citation>
    <PMID>19820010</PMID>
  </reference>
  <reference>
    <citation>Pattou F, Kerr-Conte J, Wild D. GLP-1-receptor scanning for imaging of human beta cells transplanted in muscle. N Engl J Med. 2010 Sep 23;363(13):1289-90. doi: 10.1056/NEJMc1004547.</citation>
    <PMID>20860517</PMID>
  </reference>
  <reference>
    <citation>Christ E, Wild D, Ederer S, Béhé M, Nicolas G, Caplin ME, Brändle M, Clerici T, Fischli S, Stettler C, Ell PJ, Seufert J, Gloor B, Perren A, Reubi JC, Forrer F. Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging study. Lancet Diabetes Endocrinol. 2013 Oct;1(2):115-22. doi: 10.1016/S2213-8587(13)70049-4. Epub 2013 Jul 25.</citation>
    <PMID>24622317</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2014</study_first_submitted>
  <study_first_submitted_qc>April 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2014</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Localisation of Insulinoma</keyword>
  <keyword>beta-cell imaging</keyword>
  <keyword>exendin-4</keyword>
  <keyword>68Ga-DOTA-exendin-4 PET/CT</keyword>
  <keyword>111In-DOTA-exendin-4 SPECT/CT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoglycemia</mesh_term>
    <mesh_term>Insulinoma</mesh_term>
    <mesh_term>Congenital Hyperinsulinism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

